Kyntra Bio (LTS:0IL8) Total Premiums Earned

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0IL8 Kyntra Bio Inc LTS:0IL8
34 GF Score
Price $8.50
GF Value $4.70
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Kyntra Bio Total Premiums Earned?

Total Premiums Earned only applies to insurance companies.

LTS:0IL8
34GF Score
Kyntra Bio Inc LTS:0IL8
Total Premiums Earned is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Kyntra Bio (LTS:0IL8) Overvalued in 2026?

Based on GuruFocus' analysis, Kyntra Bio stock appears to be overvalued. The current stock price of $8.50 is trading 80.8% above its estimated GF Value™ of $4.70. GuruFocus considers Kyntra Bio to be Significantly Overvalued.

Key valuation signals for LTS:0IL8:

  • Total Premiums Earned:
  • GF Value™: $4.70 vs. price of $8.50 (80.8% above fair value)
  • GF Score™: 34/100 with 9 warning signs

No single metric tells the full story. See the LTS:0IL8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kyntra Bio Business Description

Address 350 Bay Street, Suite 100, No. 6009, San Francisco, CA, USA, 94133
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
34GF Score

Get the complete analysis for LTS:0IL8

Total Premiums Earned is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.50
Price
$4.70
GF Value